<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39381951</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1029-2403</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Leukemia &amp; lymphoma</Title><ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation></Journal><ArticleTitle>Early impact of treatment modifications adopted for acute lymphoblastic leukemia during SARS-CoV-2 pandemic; a single center experience and lessons for LMICs.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>7</EndPage><MedlinePgn>1-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/10428194.2024.2411432</ELocationID><Abstract><AbstractText>Treatment modifications adopted during pandemic aimed at reducing infection, myelosuppression, and optimizing hospital resources. This study evaluated outcomes for pediatric patients with ALL who had treatment modifications during pandemic compared to historical cohorts at the National Cancer Institute, Cairo University, Egypt. Bi-directional cohort study included 378 patients. Treatment modifications included omission of specific drugs or adjusting chemotherapy schedules to 6-mercaptopurine/methotrexate. Median follow-up were 45.1 and 43.2 months, for cohorts (A) and (B), respectively. The three-year overall survival were 84.9% and 87.5% (<i>p</i> = .48) and three-year relapse free survival were 82.8% and 86.5% (<i>p</i> = .11) for cohorts (A) and (B), respectively. Infection-related mortality was 11% and 4.4% for cohorts (A) and (B), respectively (<i>p</i> = .03). Treatment modifications adopted during the pandemic did not adversely affect the outcome of patients with ALL and notably reduced infection-related deaths. Longer follow-up is warranted to validate these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohammad</LastName><ForeName>Esraa Maged</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0009-0003-3439-5784</Identifier><AffiliationInfo><Affiliation>Pediatric Oncology, National Cancer Institute, Cairo University, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Ayadi</LastName><ForeName>Moatasem</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9791-0104</Identifier><AffiliationInfo><Affiliation>Pediatric Oncology, National Cancer Institute, Cairo University, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamel</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Oncology, National Cancer Institute, Cairo University, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebeid</LastName><ForeName>Emad</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pediatric Oncology, National Cancer Institute, Cairo University, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Leuk Lymphoma</MedlineTA><NlmUniqueID>9007422</NlmUniqueID><ISSNLinking>1026-8022</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALL</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">pediatric</Keyword><Keyword MajorTopicYN="N">treatment modifications</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>7</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>7</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39381951</ArticleId><ArticleId IdType="doi">10.1080/10428194.2024.2411432</ArticleId></ArticleIdList></PubmedData></PubmedArticle>